Suppr超能文献

共价药物的复兴。

The resurgence of covalent drugs.

机构信息

Avila Therapeutics, 100 Beaver Street, Waltham, Massachusetts 02453, USA.

出版信息

Nat Rev Drug Discov. 2011 Apr;10(4):307-17. doi: 10.1038/nrd3410.

Abstract

Covalent drugs have proved to be successful therapies for various indications, but largely owing to safety concerns, they are rarely considered when initiating a target-directed drug discovery project. There is a need to reassess this important class of drugs, and to reconcile the discordance between the historic success of covalent drugs and the reluctance of most drug discovery teams to include them in their armamentarium. This review surveys the prevalence and pharmacological advantages of covalent drugs, discusses how potential risks and challenges may be addressed through innovative design, and presents the broad opportunities provided by targeted covalent inhibitors.

摘要

共价药物已被证明是治疗各种适应症的有效疗法,但在启动靶向药物发现项目时,由于安全性问题,它们很少被考虑。有必要重新评估这一重要类别的药物,并调和共价药物的历史成功与大多数药物发现团队不愿将其纳入其武器库之间的不和谐。本文综述了共价药物的普遍性和药理学优势,讨论了如何通过创新设计来解决潜在的风险和挑战,并介绍了靶向共价抑制剂带来的广泛机会。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验